DrugPatentWatch Database Preview
Carvedilol phosphate - Generic Drug Details
see a sample report or, see our see our flat-rate plans
What are the generic drug sources for carvedilol phosphate and what is the scope of carvedilol phosphate freedom to operate?
Carvedilol phosphate
is the generic ingredient in two branded drugs marketed by Impax Labs Inc, Sun Pharm Industries, and Smithkline Beecham, and is included in three NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.There are thirty-six drug master file entries for carvedilol phosphate. Five suppliers are listed for this compound.
Summary for carvedilol phosphate
| US Patents: | 2 |
| Tradenames: | 2 |
| Applicants: | 3 |
| NDAs: | 3 |
| Drug Master File Entries: | 36 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 119 |
| Clinical Trials: | 5 |
| Patent Applications: | 6,342 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for carvedilol phosphate |
| DailyMed Link: | carvedilol phosphate at DailyMed |
Pharmacology for carvedilol phosphate
| Drug Class | alpha-Adrenergic Blocker beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists |
Synonyms for carvedilol phosphate
| (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol |
| (2RS)-1-(9H-Carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol phosphate salt (1:1) |
| (2RS)-1-(9H-Carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol phosphate salt (1:1) hemihydrate |
| (2RS)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol phosphate salt (1:1) hemihydrate |
| [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine |
| 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol |
| 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; phosphoric acid; hydrate |
| 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol |
| 1-9H-(Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate hemihydrate |
| 102641-EP2270011A1 |
| 102641-EP2272841A1 |
| 102641-EP2275420A1 |
| 102641-EP2298764A1 |
| 102641-EP2298765A1 |
| 102641-EP2301936A1 |
| 107741-96-8 |
| 1196658-85-1 |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)- |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate (1:1) |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate (salt), hydrate (2:2:1) |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate, hydrate (1:1:1) |
| 309C892 |
| 374779-45-0 |
| 610309-89-2 |
| 72956-09-3 |
| 956C093 |
| AB0008431 |
| AB00639903_10 |
| AB00639903_11 |
| AB00639903_12 |
| AB00639903-07 |
| AB00639903-09 |
| AB1004830 |
| AC-1641 |
| AC1L1E0B |
| AK163147 |
| AKOS005554967 |
| AKOS026749869 |
| AN-14749 |
| AN-27765 |
| API0001873 |
| Artist |
| Artist (TN) |
| Atlana Pharma brand of carvedilol |
| AX8120145 |
| BBL029064 |
| BC204100 |
| BCP0726000253 |
| BCP9000493 |
| BDBM25759 |
| BG0129 |
| Bio-0014 |
| BIS(1-(9H-CARBAZOL-4-YLOXY)-3-{[2-(2-METHOXYPHENOXY)ETHYL]AMINO}PROPAN-2-OL) BIS(PHOSPHORIC ACID) HYDRATE |
| BM 14,190 |
| BM 14.190 |
| BM 14190 |
| BM-14-190 |
| BM-14.190 |
| BM-14190 |
| BRD-A10977446-001-04-8 |
| BRD-A10977446-045-01-1 |
| C-21835 |
| C06875 |
| C24H26N2O4 |
| C24H31N2O9P |
| Carloc |
| Carloc (TN) |
| carvedilol |
| Carvedilol (JAN/USAN/INN) |
| Carvedilol (phosphate hemihydrate) |
| Carvedilol [USAN:INN:BAN:JAN] |
| Carvedilol [USAN:USP:INN:BAN:JAN] |
| Carvedilol 1.0 mg/ml in Methanol |
| Carvedilol dihydrogen phosphate hemihydrate |
| Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard |
| carvedilol HCl |
| Carvedilol hydrochloride |
| Carvedilol phosphate (USAN) |
| Carvedilol phosphate [USAN] |
| Carvedilol phosphate anhydrous |
| Carvedilol phosphate hemihydrate |
| Carvedilol phosphate hydrate (JAN) |
| Carvedilol phosphate monohydrate |
| carvedilol, (+-)-isomer |
| carvedilol, (R)-isomer |
| carvedilol, (S)-isomer |
| Carvedilol, >=98% (HPLC), solid |
| carvedilol, 14C-labeled |
| Carvedilol, European Pharmacopoeia (EP) Reference Standard |
| Carvedilol, pharmaceutical secondary standard; traceable to USP and PhEur |
| Carvedilol, United States Pharmacopeia (USP) Reference Standard |
| Carvedilolum |
| Carvedilolum [Latin] |
| carvediol |
| CC-25436 |
| CCG-100917 |
| CCG-207952 |
| CCG-213312 |
| CHEBI:3441 |
| CHEMBL1201167 |
| CHEMBL723 |
| Coreg |
| Coreg (TN) |
| Coreg CR |
| Coreg CR (TN) |
| Coropres |
| Coropress |
| CPD000449280 |
| CS-1194 |
| CTK3J2232 |
| D00255 |
| D03415 |
| D0W9LX |
| DB01136 |
| Dibloc |
| Dilatrend |
| Dilatrend (TN) |
| DQ 2466 |
| DQ-2466 |
| DTXSID8022747 |
| EG-P042 |
| Eucardic |
| Eucardic (TN) |
| FT-0603059 |
| FT-0652640 |
| GlaxoSmithKline brand of carvedilol |
| GTPL551 |
| HMS2051N03 |
| HMS2089B09 |
| HMS2093E12 |
| HMS3261E15 |
| HMS3269N11 |
| HMS3393N03 |
| HMS3655O14 |
| HSDB 7044 |
| HY-B0006 |
| I06-0064 |
| I06-1477 |
| J10039 |
| JAYBFQXVKDGMFT-UHFFFAOYSA-N |
| KB-75594 |
| KBio2_002145 |
| KBio2_004713 |
| KBio2_007281 |
| KBio3_002323 |
| KBioGR_001252 |
| KBioSS_002145 |
| Kredex |
| KS-00000XRT |
| KS-1037 |
| KSC492E3F |
| L001243 |
| Lakeside brand of carvedilol |
| LHNYXTULDSJZRB-UHFFFAOYSA-N |
| LP00347 |
| LS-121875 |
| LS-186601 |
| MCULE-7944987271 |
| MFCD00864692 |
| MLS000758299 |
| MLS000759508 |
| MLS001424092 |
| MLS006011886 |
| MolPort-003-666-814 |
| NC00167 |
| NCGC00167832-01 |
| NCGC00167832-02 |
| NCGC00167832-03 |
| NCGC00167832-04 |
| NCGC00261032-01 |
| NSC-751177 |
| NSC-758694 |
| NSC751177 |
| NSC758694 |
| OGHNVEJMJSYVRP-UHFFFAOYSA-N |
| Pharmakon1600-01504257 |
| PL008198 |
| PL039781 |
| PL061817 |
| PL068260 |
| PubChem18218 |
| Q-200801 |
| Querto |
| Roche brand of carvedilol |
| RTR-037608 |
| s1831 |
| SAM001246736 |
| SAM001247021 |
| SBI-0206771.P001 |
| SC-13445 |
| SCHEMBL10082334 |
| SCHEMBL13287211 |
| SCHEMBL194220 |
| SCHEMBL22293 |
| SCHEMBL599530 |
| SK&F-105517 |
| SK&F-105517-D |
| SKF 105517 |
| SKF 105517D |
| SMR000449280 |
| SPBio_001885 |
| Spectrum_001665 |
| Spectrum2_001673 |
| Spectrum3_001182 |
| Spectrum4_000636 |
| Spectrum5_001436 |
| SR-01000759289 |
| SR-01000759289-9 |
| ST24036957 |
| STK621453 |
| TL8005080 |
| Tox21_500347 |
| TR-037608 |
| W-5131 |
| W0023 |
| Z2786051695 |
US Patents and Regulatory Information for carvedilol phosphate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Impax Labs Inc | CARVEDILOL PHOSPHATE | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 204717-002 | May 7, 2018 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-003 | Oct 20, 2006 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for carvedilol phosphate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for carvedilol phosphate
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0213175 | ➤ Sign Up |
| China | 103333099 | ➤ Sign Up |
| Japan | 2013241450 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2005099671 | ➤ Sign Up |
| Norway | 329710 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: